Annovis Bio (ANVS) announced that all Company’s patents have been successfully transferred from the original form of buntanetap and rewritten to cover the new crystal form. Every patent family is now represented for both forms of the Company’s drug candidate, securing comprehensive protection, which extends to 2046. Building on its foundational patent for the treatment of chronic neurodegenerative conditions, the Company has systematically expanded its coverage to include patents for the use of the original compound. Since then, Annovis has developed a robust IP portfolio which includes patents protecting the composition of matter, mechanism of action, applications of buntanetap for multiple indications, and its combination with other drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors
- Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study
- Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors?
- Annovis Bio’s Promising Alzheimer’s Study: A Potential Game Changer?
- Annovis Bio rises 16.3%